Recent News

What makes a good antibody–drug conjugate? – Martin De Cecco, Daniel N. Galbraith & Lisa L. McDermottt

Feb 2021

Beacon Targeted Therapies announces the launch of Beacon Oncolytic Viruses

Jul 2020

Cell Therapy 2.0

Jul 2020

Overcoming Challenges in the Development of Anticancer ADCs

Jun 2020

Immuno-oncology cell therapies: commercial considerations and strategies for the new decade

Jun 2020

Beacon Targeted Therapies announces the launch of Beacon Gene Therapy

May 2020

Frontiers in Oncology – Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Apr 2020

Hot Topics at CAR-TCR 2020

Apr 2020

Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials

Feb 2020

TCR Therapies Summit 2020 Magazine

Feb 2020

Drug developers take fresh aim at ‘guided-missile’ cancer drugs

Jan 2020

CAR-TCR Europe Summit 2020 Magazine

Jan 2020

World ADC London 2020 Magazine

Jan 2020

Innate Killer Summit 2020 Magazine

Jan 2020

From Mylotarg to Polivy: Ebbs and flows, successes and woes of ADCs

Nov 2019

Trends & Forecasts – Tenacious ADCs

Nov 2019

World ADC San Diego Magazine 2019

Sep 2019

Beacon Targeted Therapies expands on Adoptive Cell Clinical Trial and Drug Database Solutions

Sep 2019

Biomarkers for Checkpoint Inhibition and Their Clinical Utility – Timothy James Fabisiak, B.A.

Jul 2019

Bispecific antibodies: a mechanistic review of the pipeline Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren

Jun 2019

Beacon Targeted Therapies Launches Beacon Adoptive Cell

May 2019

The Evolving Shape of the ADC Market: The Widening Application of ADCs and Manufacturing Improvements Meeting Demand – Charlie Johnson, CEO of ADC Bio, adcbio.com

Mar 2019

Antibodies to watch in 2019 – Hélène Kaplon & Janice M. Reichert

Dec 2018
logo